DA Davidson maintains Buy rating on Peoples Bancorp, $42 price target

Peoples Bancorp (PEBO) to acquire Capital Bancorp in a $728M all-stock deal. The merger is expected to close in H1 2027, with 2027 EPS accretion of ~19% and initial TBV dilution of ~10.8%. The combined entity will have ~$14B in assets and $10B in loans.

PEOPLES BANCORP INC (PEBO) filed an SEC Form 8-K — Other Events. Filed by: Peoples Bancorp, Inc. (Commission File No.: 000-16772) Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Capital Bancorp, Inc. (Commission File N

Keefe Bruyette & Woods reiterated a Market Perform rating on Peoples Bancorp (PEBO) with a $42 price target after its acquisition of CBNK, which increases assets to $14B and is expected to boost EPS by 20%. The bank's Q2 2026 EPS missed estimates but revenue exceeded forecasts. Analysts have raised earnings estimates and price targets.

Peoples Bancorp (PEBO) is acquiring Capital Bancorp for $728M, expanding its national reach. The deal is expected to create a combined company with $14B in assets, $10B in loans, and $11B in deposits. Capital has shown strong financial performance, with 20% annual growth in assets, loans, and deposits over the past three years. Peoples expects 19% EPS accretion by 2027 and an IRR above 25%. The transaction is subject to regulatory approval and is expected to close in late 2024.

Peoples Bancorp (PEBO) announced an all-stock acquisition of Capital Bancorp, valued at $728M. PEBO shares fell 5.87% as investors reacted to the 50% share dilution from issuing 18M new shares. The combined entity will have $14B in assets, with the deal expected to close in 2027, pending approvals.

Peoples Bancorp (PEBO) shares fell 5.5% to $36.72 after announcing an all-stock acquisition of Capital Bancorp (CBNK) valued at $728.1M. The deal, expected to close in H1 2027, will create a combined entity with $14B in assets. The stock decline reflects dilution concerns and an investor rights law firm's investigation into the merger.